Publicaciones recientes

  1. Strategies for Continued Successful Treatment in Patients with Alzheimer's Disease: An Overview of Switching Between Pharmacological Agents. Blesa, R, Toriyama, K, Ueda, K et al. Curr Alzheimer Res 2018

  2. Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. Morenas-Rodríguez, E, Sala, I, Subirana, A et al. J. Alzheimers Dis. 2018

  3. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. Lleó, A, Irwin, DJ, Illán-Gala, I et al. JAMA Neurol 2018

  4. Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. Cantero, JL, Atienza, M, Sanchez-Juan, P et al. Neurobiol. Aging 2018

  5. Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. Jimenez, A, Pegueroles, J, Carmona-Iragui, M et al. Oncotarget 2017

  6. Synaptic phosphorylated α-synuclein in dementia with Lewy bodies. Colom-Cadena, M, Pegueroles, J, Herrmann, AG et al. Brain 2017

  7. Cortical microstructural changes along the Alzheimer's disease continuum. Montal, V, Vilaplana, E, Alcolea, D et al. Alzheimers Dement 2018

  8. Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation. Dols-Icardo, O, García-Redondo, A, Rojas-García, R et al. J. Neurol. Neurosurg. Psychiatry 2018

  9. The pitfalls of biomarker-based classification schemes. Illán-Gala, I, Vilaplana, E, Pegueroles, J et al. Alzheimers Dement 2017

  10. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. Querol-Vilaseca, M, Colom-Cadena, M, Pegueroles, J et al. J Neuroinflammation 2017

  11. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Alcolea, D, Vilaplana, E, Suárez-Calvet, M et al. Neurology 2017

  12. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. Sala, I, Illán-Gala, I, Alcolea, D et al. J. Alzheimers Dis. 2017

  13. Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease. Carmona-Iragui, M, Balasa, M, Benejam, B et al. Alzheimers Dement 2017

  14. Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. Cervera-Carles, L, Alcolea, D, Estanga, A et al. Neurobiol. Aging 2017

  15. Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome. Carmona-Iragui, M, Santos, T, Videla, S et al. J. Alzheimers Dis. 2017

  16. Longitudinal brain structural changes in preclinical Alzheimer's disease. Pegueroles, J, Vilaplana, E, Montal, V et al. Alzheimers Dement 2017

  17. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. Parnetti, L, Eusebi, P, Lleó, A et al. Front Neurol Neurosci 2016

  18. Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. Morenas-Rodríguez, E, Cervera-Carles, L, Vilaplana, E et al. J. Alzheimers Dis. 2016

  19. Assessing the role of TUBA4A gene in frontotemporal degeneration. Dols-Icardo, O, Iborra, O, Valdivia, J et al. Neurobiol. Aging 2016

  20. Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. Carmona-Iragui, M, Fernández-Arcos, A, Alcolea, D et al. J. Alzheimers Dis. 2016

Search PubMed